Evidence map›Paper›PMID 39559932›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Positron emission tomography harmonization in the Alzheimer's Disease Neuroimaging Initiative: A scalable and rigorous approach to multisite amyloid and tau quantification.

Susan M Landau, Theresa M Harrison, Suzanne L Baker, Martin S Boswell, JiaQie Lee, Jacinda Taggett, Tyler J Ward, Trevor Chadwick, Alice Murphy, Charles DeCarli and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  7. Classification of tau status with machine learning models in amyloid-positive cohorts.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Elevated AD biomarkers do not explain cognitive performance in a community-recruited clinical trial cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Susan M LandauNeuroscience Department, University of California, Berkeley, California, USA.
Theresa M HarrisonNeuroscience Department, University of California, Berkeley, California, USA.
Suzanne L BakerMolecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
Martin S BoswellMolecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
JiaQie LeeNeuroscience Department, University of California, Berkeley, California, USA.
Jacinda TaggettNeuroscience Department, University of California, Berkeley, California, USA.
Tyler J WardNeuroscience Department, University of California, Berkeley, California, USA.
Trevor ChadwickNeuroscience Department, University of California, Berkeley, California, USA.
Alice MurphyNeuroscience Department, University of California, Berkeley, California, USA.
Charles DeCarliUniversity of California, Davis, California, USA.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Robert A KoeppeDepartment of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
William J JagustNeuroscience Department, University of California, Berkeley, California, USA.
U.S. POINTER Study Group and for the Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER · 2019 to 2026
$120.9M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)U19NS120384 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Kumar B. Rajan · 2020 to 2026
$61.9M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
US POINTER Neuroimaging Ancillary StudyR01AG062689 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI LANDAU, SUSAN M · 2019 to 2025
$47.3M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
Alzheimer's Association U.S. POINTER-19-611541Alzheimer's Disease Neuroimaging Initiative (ADNI)Center for Alzheimer's and Related Dementias (CARD) AG000546NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NCRR NIH HHS U24 RR021382NIA NIH HHS K01 AG078443NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P20 AG068053NIA NIH HHS P20 AG068077NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG053760NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062428NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072980NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG033514NIA NIH HHS P50 AG047266NIA NIH HHS P50 AG047270NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG019771NIA NIH HHS R01 AG021910NIA NIH HHS R01 AG043434NIA NIH HHS R01 AG045571NIA NIH HHS R01 AG052560NIA NIH HHS R01 AG053509NIA NIH HHS R01 AG053993NIA NIH HHS R01 AG054110NIA NIH HHS R01 AG055005NIA NIH HHS R01 AG056031NIA NIH HHS R01 AG056258NIA NIH HHS R01 AG056531NIA NIH HHS R01 AG058724NIA NIH HHS R01 AG061788NIA NIH HHS R01 AG062276NIA NIH HHS R01 AG062542NIA NIH HHS R01 AG062689NIA NIH HHS R01 AG067781NIA NIH HHS R01 AG068338NIA NIH HHS R01 AG069453NIA NIH HHS R01 AG073235NIA NIH HHS R01 AG077444NIA NIH HHS R35 AG072262NIA NIH HHS R56 AG045571NIA NIH HHS R56 AG074321NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG063911NIA NIH HHS U19 AG073153NIA NIH HHS U24 AG067418NIA NIH HHS U24 AG072122NIBIB NIH HHS R01 EB009352NIDCD NIH HHS R01 DC008552NIH HHS S10 OD026738NIH/NIA AG067418NIMH NIH HHS P50 MH071616NINDS NIH HHS P30 NS098577NINDS NIH HHS R01 NS075075NINDS NIH HHS U19 NS120384RRD VA I01 RX001534RRD VA I21 RX001381Takeda Pharmaceutical Company
6 · The paper itself

Abstract

introductionA key goal of the Alzheimer's Disease NeuroImaging Initiative (ADNI) positron emission tomography (PET) Core is to harmonize quantification of β-amyloid (Aβ) and tau PET image data across multiple scanners and tracers.

methodsWe developed an analysis pipeline (Berkeley PET Imaging Pipeline, B-PIP) for ADNI Aβ and tau PET images and applied it to PET data from other multisite studies. Steps include image pre-processing, refacing, magnetic resonance imaging (MRI)/PET co-registration, visual quality control (QC), quantification of tracer uptake, and standardization of Aβ and tau standardized uptake value ratios (SUVrs) across tracers.

resultsMeasurements from 10,105 cross-sectional and longitudinal Aβ and tau PET scans acquired in several studies between 2010 and 2024 can be processed, harmonized, and directly merged across tracers and cohorts. DISCUSSION: The B-PIP developed in ADNI is a scalable image harmonization approach used in several observational studies and clinical trials that facilitates rigorous Aβ and tau PET quantification and data sharing. HIGHLIGHTS: Quantitative results from ADNI Aβ and tau PET data are generated using a rigorous, scalable image processing pipeline This pipeline has been applied to PET data from several other large, multisite studies and trials Quantitative outcomes are harmonizable across studies and are shared with the scientific community.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBrainNeuroimagingPositron-Emission Tomographytau ProteinsCross-Sectional StudiesHumansImage Processing, Computer-AssistedLongitudinal StudiesMagnetic Resonance ImagingMaleAmyloid beta-Peptidestau ProteinsAlzheimer's diseaseAβ PETtau PET

Identifiers

PMID39559932
PMCPMC11772732

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.